IFNG and neoplasm: To assess the activation of Interferon (IFN)-γ activated site signaling [28], which also upregulates PD-L1 on canine tumor cell lines [10], we monitored major histocompatibility class II (MHCII) as a proxy for cIFN-γ signaling.